ReviewThe Lancet. Microbe2025
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.
Review in The Lancet. Microbe, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed.
- Can we escape from top-priority ESKAPE pathogens?Emerging microbes & infections · 2026Review
- Integrated in-silico and in-vitro evaluation of silybin as a potential quorum-sensing modulator against Acinetobacter baumannii and Staphylococcus aureus.World journal of microbiology & biotechnology · 2026Article
- Bioactivity-driven prediction of antibacterial synergy using machine learning models.PLoS computational biology · 2026Article
- Non-Traditional Antibacterial Agents Relevant to the WHO 2024 Priority Pathogens: A Structured Update of the Clinical Pipeline.Antibiotics (Basel, Switzerland) · 2026Review
- WHO assessment of the preclinical antifungal pipeline: evaluating innovation and preparedness in the face of emerging fungal threats.The Lancet. Microbe · 2026Review
- Defining a target product profile for antimicrobials to treat severe paediatric bacterial enteric infections in low- and medium-income countries, caused byJAC-antimicrobial resistance · 2026Review
- Novel Therapeutic Approaches and Alternatives to Antibiotic Therapy for Drug-Resistant Intra-Abdominal Infections.Antibiotics (Basel, Switzerland) · 2026Review
- Multi-Target Bioactivity ofPharmaceuticals (Basel, Switzerland) · 2026Article
- Barriers to accessing newer antibiotics in countries with high burden of bacterial antimicrobial resistant infections-a qualitative study.The Lancet regional health. Western Pacific · 2026Article
- Nanomaterial strategies for antibiotic-resistant infections: Mechanistic frameworks, rational design, and clinical translation.Materials today. Bio · 2026Review
- Synergistic Inhibition ofMicroorganisms · 2026Article
- Article
- X-ray Co-crystal Structure of a Novel Pseudomonas aeruginosa DXPS Inhibitor Reveals an Unusual Allosteric Binding Pocket.Research square · 2026Article
- Generative active learning guided discovery of a tobramycin and ciprofloxacin adjuvant against multidrug-resistantActa pharmaceutica Sinica. B · 2026Article
- A novel approach to combatMicrobiology spectrum · 2026Article
- Screening the antimicrobial properties of snake venoms: an iterative fractionation approach.Access microbiology · 2026Article
- Impact of Enhanced Infection Control Measures on Hospital-Acquired Carbapenem-ResistantInfection and drug resistance · 2026Article
- Antibacterial activities of novel peptide nucleic acids targetingMolecular therapy. Nucleic acids · 2025Article
- Dilution susceptibility testing method evaluation for the combination of ceftibuten and avibactam against Enterobacterales.Journal of clinical microbiology · 2025Article
- Fixation Method Determines the Ultrastructure of the Nucleoid in Pseudomonas aeruginosa and Staphylococcus aureus.Bulletin of experimental biology and medicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Antimicrobial resistance continues to evolve and remains a leading cause of death worldwide, with children younger than 5 years being among those at the highest risk. Addressing antimicrobial resistance requires a comprehensive response, including infection prevention efforts, surveillance, stewardship, therapy appropriateness and access, and research and development. However, antimicrobial research and development is limited and lags behind the output of other fields, such as that of cancer or HIV research. The 2023 WHO analysis of the global antibacterial clinical pipeline serves as a tool to monitor and guide research and development efforts. The analysis emphasises the remaining gaps in developing a robust and effective antibacterial drug pipeline, drawing insights from trend analyses and assessment of the innovation potential of candidate antimicrobials. In the present analysis, we evaluated the activity of antibiotics against the new WHO bacterial priority pathogens list 2024, which reflects changing trends in resistance patterns, distribution of bacterial infections, and the emergence of new resistance mechanisms.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.